Albumin

ApprovedCompleted
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Cirrhosis

Conditions

Cirrhosis, Ascites

Trial Timeline

Jul 1, 2009 → Apr 1, 2014

About Albumin

Albumin is a approved stage product being developed by Grifols for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00968695. Target conditions include Cirrhosis, Ascites.

What happened to similar drugs?

5 of 10 similar drugs in Cirrhosis were approved

Approved (5) Terminated (0) Active (5)

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02479802Phase 2Completed
NCT02878733Pre-clinicalCompleted
NCT00968695ApprovedCompleted

Competing Products

20 competing products in Cirrhosis

See all competitors
ProductCompanyStageHype Score
SYNB1020SynlogicPhase 1/2
14
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Bumetanide + FurosemideJohnson & JohnsonPhase 3
47
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
ZibotentanAstraZenecaPhase 1
29
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozinAstraZenecaPhase 2
27
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozinAstraZenecaPhase 2
35
ARQ 197MerckPhase 1
29
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved
43
Telbivudine + Enecavir + AdefovirNovartisApproved
39
Serelaxin + PlaceboNovartisPhase 2
35
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
PasireotideNovartisPhase 1
29
HPN-100 + PlaceboAmgenPhase 2
35
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mgGilead SciencesPhase 2
27
TDF/FTC/LPV/r + PlaceboGilead SciencesPre-clinical
18
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg CapsuleGilead SciencesPhase 2
35